Gilead Sciences, Inc. (GILD) Holdings Trimmed by Cypress Capital Group

Cypress Capital Group reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,819 shares of the biopharmaceutical company’s stock after selling 2,980 shares during the period. Cypress Capital Group’s holdings in Gilead Sciences were worth $2,892,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of GILD. Mutual Advisors LLC boosted its position in shares of Gilead Sciences by 9.2% during the 2nd quarter. Mutual Advisors LLC now owns 10,253 shares of the biopharmaceutical company’s stock worth $726,000 after purchasing an additional 863 shares in the last quarter. Putnam Investments LLC boosted its position in shares of Gilead Sciences by 6.2% during the 2nd quarter. Putnam Investments LLC now owns 3,746,357 shares of the biopharmaceutical company’s stock worth $265,392,000 after purchasing an additional 218,743 shares in the last quarter. HPM Partners LLC boosted its position in shares of Gilead Sciences by 6.0% during the 2nd quarter. HPM Partners LLC now owns 46,532 shares of the biopharmaceutical company’s stock worth $3,296,000 after purchasing an additional 2,630 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its position in shares of Gilead Sciences by 297.7% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 179,250 shares of the biopharmaceutical company’s stock worth $3,754,000 after purchasing an additional 134,177 shares in the last quarter. Finally, OLD Mutual Customised Solutions Proprietary Ltd. boosted its position in shares of Gilead Sciences by 2.5% during the 2nd quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 74,971 shares of the biopharmaceutical company’s stock worth $5,311,000 after purchasing an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 78.04% of the company’s stock.

Shares of NASDAQ GILD opened at $73.38 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54. The stock has a market capitalization of $95.89 billion, a P/E ratio of 10.64, a price-to-earnings-growth ratio of -5.64 and a beta of 1.02. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business had revenue of $5.65 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter last year, the firm earned $2.56 EPS. The firm’s revenue for the quarter was down 20.9% compared to the same quarter last year. sell-side analysts expect that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, September 13th. This represents a $2.28 annualized dividend and a yield of 3.11%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

A number of equities analysts have recently issued reports on GILD shares. Mizuho reissued a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research report on Friday, August 10th. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 18th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 26th. Raymond James started coverage on shares of Gilead Sciences in a research report on Thursday, June 28th. They set a “strong-buy” rating and a $93.00 price objective on the stock. Finally, ValuEngine cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, August 20th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $88.30.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total value of $3,892,500.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 150,000 shares of company stock valued at $11,141,000. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Closed-End Mutual Funds

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply